FREQUENCY OF RAISED SERUM LACTATE DEHYDROGENASE IN PATIENTS WITH JAK2 POSITIVE POLYCYTHEMIA VERA
Abstract
Background: Serum Lactate Dehydrogenase (LDH) is an easily available bio marker used to determine prognosis in various Myeloproliferative Neoplasms (MPN). Its utility in Polycythemia Vera (PV) is yet to be accessed. The purpose of this study was to determine the frequency of raised serum LDH in patients with JAK2 V617F positive PV patients and its clinic-pathological association. Materials and methods: A cross-sectional study using non probability consecutive sampling was conducted at our institute from July 2018 to June 2019. Adult patients of either gender, newly diagnosed with JAK-2 V617F positive PV were included. Patients’ demographics, clinical characteristics and baseline CBC and LDH levels were analyzed. Stratification was done with regards to age, gender, diabetes mellitus, hypertension, splenomegaly and thrombosis to see the effect of these modifiers on patients with raised LDH by using Chi Square test. P value of ≤0.05 was considered as significant. Results: Forty patients were inducted in the study with male to female ratio of 2:1. Twenty two (55%) patients had raised LDH levels and showed significant association with diabetes mellitus (p=0.001), splenomegaly (p=0.001) and thrombosis (p=0.018). Conclusion: This study observed raised LDH levels in almost half of JAK2 V617F positive PV patients. It warrants a larger scale study and suggests the value of plasma LDH to be used as a future prognostic marker in PV.Keywords: Serum lactate dehydrogenase, PolycythemiaVera, Diabetes mellitus, hypertension, JAK 2 V617F mutation, Myeloproliferative Neoplasm, Pakistan.References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391–405.
Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: insights into pathophysiology and treatments in 2017. Mol Med 2018;24(1):11.
Scott LM, Linda M. The molecular genetics of polycythemia vera. Advances in Genetic Research. 16th ed. New York, NY, United States: Nova Science Publishers, 2016; p.101–22.
Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014;89(6):581–7.
Orphanet. Polycythemia vera 2019. [Internet]. [cited 2020 Aug]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=729
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117(10):755–61.
Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93(3):372–80.
Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemiavera: a population-based study of 327 patients. Br J Haematol 2013;160 (2):251–4.
Shah S, Mudireddy M, Hanson CA, Ketterling RP, Gangat N, Pardanani A, et al. Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer J 2017;7(12):657.
Mudireddy M, Barraco D, Hanson CA, Pardanani A, Gangat N, Tefferi A. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. Am J Hematol 2017;92(5):454–59.
Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, et al. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 2019;19(1):53–63.
Yadav C, Ahmad A, D'Souza B, Agarwal A, Nandini M, Ashok PK, et al. Serum Lactate Dehydrogenase in Non-Hodgkin's Lymphoma: A Prognostic Indicator. Indian J Clin Biochem 2016;31(2):240–2.
Chen C, Zhu YH, Huang JA. Clinical evaluation of potential usefulness of serum lactate dehydrogenase level in follow-up of small cell lung cancer. J Cancer Res Ther 2018;14(Suppl):S336–40.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC, 2008; p.40–53.
Deme D, Telekes A. Prognostic importance of lactate dehydrogenase (LDH) in oncology. Orv Hetil 2017;158(50):1977–88.
Roche diagnostics. Cobas-C501 manual (available at https://diagnostics.roche.com/global/en/products/instruments/cobas-c-501.html)
Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, et al. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not havesignificantly worseoutcome. Leuk Res 2013;37(11):1472–1476.
Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, et al. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 2017;102(9):1511–8.
Tefferi A, Barraco D, Cerquozzi S, Lasho TL, Hanson CA, Ketterling RP, et al. Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood 2016;128(22):3111.
Tefferi, A, Rumi E, FinazzG , Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27(9):1874–81.
Gianelli U, Cattaneo D, Bossi A, Cortinovis I, Boiocchi L, Liu YC, et al. The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. Mod Patho 2017;30(2):169–79.
Mazzotta S, Guerranti R, Gozzetti A, Bucalossi A, Bocchia M, Sammassimo S, et al. Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: a metabolic adaptation? Hematology 2006;11(4):239–44.
Sultan S, Irfan SM, Murad S. Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera - a Five Year Experience from a Tertiary Care Center. Asian Pac J Cancer Prev 2016;17(3):1531–3.
Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122(13):2176–84.
Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research. Ann Hematol 2014;93(12):1953–63.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016;9:18.
Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol 2012;87(11):1003–5.
Shaikh MS, Shaikh MU, Adil SN, Khurshid M, Ahmed ZA. Clinico-pathological profile and outcomes of patients with polycythaemiavera, essentialthrombocythaemia and idiopathic myelofibrosis: a tertiary care center experience from southern Pakistan. J Ayub Med Coll Abbottabad 2016;28(2):293–7.
Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, et al. Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev 2015;16(12):5013–8.
Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, et al. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 2019;19(1):53–63.
Downloads
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
